THE NICKLES GROUP, LLC

Lobbying for OMEROS CORPORATION · Biopharmaceutical company.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Washington · House · Senate · $30,000.00 income · posted Oct 9, 2025

Lobbying activity 2

Medicare/Medicaid

Monitored separate payment policy for nonopioid alternatives. Issues involving rare disease therapies.

Health Issues

Issues related to rare pediatric disease and Priority Review Vouchers (PRVs).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.